MARKET

TLSIW

TLSIW

TriSalus Life Sciences Inc.
NASDAQ
1.480
0.000
0.00%
Closed 09:30 03/26 EDT
OPEN
--
PREV CLOSE
1.480
HIGH
--
LOW
--
VOLUME
75
TURNOVER
--
52 WEEK HIGH
2.240
52 WEEK LOW
0.8100
MARKET CAP
--
P/E (TTM)
-0.8458
1D
5D
1M
3M
1Y
5Y
1D
TRISALUS LIFE SCIENCES ANNOUNCES NEW CMS HCPCS CODE FOR TRINAV® INFUSION SYSTEM MAPPING
Reuters · 11h ago
Weekly Report: what happened at TLSIW last week (0317-0321)?
Weekly Report · 2d ago
Weekly Report: what happened at TLSIW last week (0310-0314)?
Weekly Report · 03/17 10:41
Weekly Report: what happened at TLSIW last week (0303-0307)?
Weekly Report · 03/10 10:43
Weekly Report: what happened at TLSIW last week (0224-0228)?
Weekly Report · 03/03 10:42
Weekly Report: what happened at TLSIW last week (0217-0221)?
Weekly Report · 02/24 10:42
TRISALUS LIFE SCIENCES INC - ENTERS INTO $50 MILLION CREDIT AGREEMENT
Reuters · 02/19 11:12
Weekly Report: what happened at TLSIW last week (0210-0214)?
Weekly Report · 02/17 10:40
More
About TLSIW
TriSalus Life Sciences, Inc. is an oncology focused medical technology business providing drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. Its two Food and Drug Administration (FDA) cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. Additionally, the Company is exploring the integration of its technology with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications.

Webull offers TriSalus Life Sciences Inc stock information, including NASDAQ: TLSIW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSIW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLSIW stock methods without spending real money on the virtual paper trading platform.